To measure the occupancy of brain kappa opioid receptors after single oral doses of LY2456302.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
13
Starting dose of 2 mg, administered orally, once. The potential dose range for this study is 0.2 mg to 30 mg
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
New Haven, Connecticut, United States
Change in brain kappa opioid receptor occupancy (RO) by positron emission tomography (PET)
Time frame: Baseline, after single dose of study drug
Pharmacokinetics, area under the curve (AUC)
Time frame: Days 1 and 2
Number of participants with clinically significant effects
Time frame: Baseline to study completion
Pharmacokinetics, concentration maximum (Cmax)
Time frame: Days 1 and 2
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.